CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
aprepitant +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01640340
NCT01640340N/ACompleted
CompareCT.gov

Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC).

Ohio State University Comprehensive Cancer Center·interventional·Posted Jul 13, 2012·Updated Nov 7, 2013

In Brief

A clinical study evaluating aprepitant, palonosetron hydrochloride, and 2 other interventions for Malignant Neoplasm. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Palonosetron is different from ondansetron because it stays in the body longer and may prevent nausea and vomiting for a longer period of time than ondansetron. It is standard practice to use dexamethasone and aprepitant with either ondansetron or palonosetron to prevent nausea and vomiting caused by highly emetogenic chemotherapy. Although these combinations are commonly used, they have never been compared to each other. The purpose of this study is to record the amount of nausea and vomiting, and the amount of "rescue" medication that is used with these two different anti-emetic regimens

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Neoplasm
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2012
Enrollment StartJan 1, 2011
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.0 years ago

Interventions

aprepitantdrug

Given by mouth

palonosetron hydrochloridedrug

Given IV(intervenous infusion)

ondansetrondrug

Given PO

dexamethasonedrug

Given PO